These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 24379620)

  • 1. Prospects for nucleic acid-based therapeutics against hepatitis C virus.
    Lee CH; Kim JH; Lee SW
    World J Gastroenterol; 2013 Dec; 19(47):8949-62. PubMed ID: 24379620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targets and tools: recent advances in the development of anti-HCV nucleic acids.
    Romero-López C; Sánchez-Luque FJ; Berzal-Herranz A
    Infect Disord Drug Targets; 2006 Jun; 6(2):121-45. PubMed ID: 16789875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nucleic acids-based therapeutics in the battle against pathogenic viruses.
    Haasnoot J; Berkhout B
    Handb Exp Pharmacol; 2009; 189(189):243-63. PubMed ID: 19048203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oligomeric nucleic acids as antivirals.
    Mescalchin A; Restle T
    Molecules; 2011 Jan; 16(2):1271-96. PubMed ID: 21278679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNA-based therapeutics: current progress and future prospects.
    Burnett JC; Rossi JJ
    Chem Biol; 2012 Jan; 19(1):60-71. PubMed ID: 22284355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oligonucleotide-based therapeutic options against hepatitis C virus infection.
    Trepanier JB; Tanner JE; Alfieri C
    Antivir Ther; 2006; 11(3):273-87. PubMed ID: 16759043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Future promise of siRNA and other nucleic acid based therapeutics for the treatment of chronic HCV.
    Wilson JA; Richardson CD
    Infect Disord Drug Targets; 2006 Mar; 6(1):43-56. PubMed ID: 16787303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antisense inhibitors, ribozymes, and siRNAs.
    Thompson AJ; Patel K
    Clin Liver Dis; 2009 Aug; 13(3):375-90. PubMed ID: 19628155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combating hepatitis C virus by targeting microRNA-122 using locked nucleic acids.
    Machlin ES; Sarnow P; Sagan SM
    Curr Gene Ther; 2012 Aug; 12(4):301-6. PubMed ID: 22856605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differing prospects for the future of using gene therapy to treat infections with hepatitis B virus and hepatitis C virus.
    Ely A; Arbuthnot P
    Discov Med; 2015 Sep; 20(109):137-43. PubMed ID: 26463095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New therapies on the horizon for hepatitis C: are we close?
    De Francesco R; Rice CM
    Clin Liver Dis; 2003 Feb; 7(1):211-42, xi. PubMed ID: 12691468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene therapies for hepatitis C virus.
    Verstegen MM; Pan Q; van der Laan LJ
    Adv Exp Med Biol; 2015; 848():1-29. PubMed ID: 25757613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative approaches for efficient inhibition of hepatitis C virus RNA replication by small interfering RNAs.
    Krönke J; Kittler R; Buchholz F; Windisch MP; Pietschmann T; Bartenschlager R; Frese M
    J Virol; 2004 Apr; 78(7):3436-46. PubMed ID: 15016866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Future trends in managing hepatitis C.
    McHutchison JG; Dev AT
    Gastroenterol Clin North Am; 2004 Mar; 33(1 Suppl):S51-61. PubMed ID: 15081103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNA Interference-Guided Targeting of Hepatitis C Virus Replication with Antisense Locked Nucleic Acid-Based Oligonucleotides Containing 8-oxo-dG Modifications.
    Mutso M; Nikonov A; Pihlak A; Žusinaite E; Viru L; Selyutina A; Reintamm T; Kelve M; Saarma M; Karelson M; Merits A
    PLoS One; 2015; 10(6):e0128686. PubMed ID: 26039055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapeutic oligonucleotides: a review].
    Wang X; Xian J; Chen G; Peng H
    Sheng Wu Gong Cheng Xue Bao; 2018 May; 34(5):664-675. PubMed ID: 29893074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-transcriptional inhibition of hepatitis C virus replication through small interference RNA.
    Ali Ashfaq U; Ansar M; Sarwar MT; Javed T; Rehman S; Riazuddin S
    Virol J; 2011 Mar; 8():112. PubMed ID: 21388559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver as a target for oligonucleotide therapeutics.
    Sehgal A; Vaishnaw A; Fitzgerald K
    J Hepatol; 2013 Dec; 59(6):1354-9. PubMed ID: 23770039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Experimental therapy in HCV infection].
    Inglot M; Gładysz A; Rymer W
    Przegl Epidemiol; 2005; 59(2):525-33. PubMed ID: 16190563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic nucleic acids: current clinical status.
    Sridharan K; Gogtay NJ
    Br J Clin Pharmacol; 2016 Sep; 82(3):659-72. PubMed ID: 27111518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.